News | January 07, 2024
AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan
The deal includes upfront payments, milestone payments and ongoing royalties
The deal includes upfront payments, milestone payments and ongoing royalties
Comprehensive clinical development programs being initiated for each investigational candidate
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
Medway setup a state-of-the-art Heart Institute in Chennai
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Subscribe To Our Newsletter & Stay Updated
